Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients - Brief Research Report

Autor(es):Mostrar menos -

Moraes, Adriel S. ^[1] ; Boldrini, Vinicius O. ^[1] ; Dionete, Alliny C. ^[1] ; Andrade, Marilia D. ^[1] ; Longhini, Ana Leda F. ^{[1, 2]} ; Santos, Irene ^[1] ; Lima, Amanda D. R. ^[1] ; Silva, Veronica A. P. G. ; Dias Carneiro, Rafael P. C. ^{[1, 2, 3]} ; Quintiliano, Raphael P. S. ^[1] ; Ferrari, Breno B. ^[1] ; Damasceno, Alfredo ^[2] ; Pradella, Fernando ^[1] ; Farias, Alessandro S. ^{[1, 4]} ; Tilbery, Charles P. ^[3] ; Domingues, Renan B. ^{[3, 5]} ; Senne, Carlos ^{[6, 5]} ; Fernandes, Gustavo B. P. ^{[6, 5]} ; von Glehn, Felipe ^[1] ; Brandao, Carlos Otavio ^{[1, 2]} ; Stella, Carla R. A. V. ^[2] ; Santos, Leonilda M. B. ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Neuroimmunol Unit, Campinas - Brazil

^[2] Univ Alabama Birmingham, Dept Immunol & Rheumatol, Birmingham, AL - USA

^[3] MS Clin Santa Casa Sao Paulo CATEM, Sao Paulo - Brazil

^[4] Natl Inst Sci & Technol Neuroimmunomodulat INCT N, Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Rio De Janeiro - Brazil

^[5] Senne Liquor Diag, Sao Paulo - Brazil

^[6] Hosp Israelita Albert Einstein, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN CELLULAR NEUROSCIENCE; v. 15, JUL 26 2021.
• Citações Web of Science: 0

Resumo

Background Neurofilament Light (NfL) chain levels in both cerebrospinal fluid (CSF) and serum have been correlated with the reduction of axonal damage in multiple sclerosis (MS) patients treated with Natalizumab (NTZ). However, little is known about the function of plasmacytoid cells in NTZ-treated MS patients. Objective To evaluate CSF NfL, serum levels of soluble-HLA-G (sHLA-G), and eventual tolerogenic behavior of plasmacytoid dendritic cells (pDCs) in MS patients during NTZ treatment. Methods CSF NfL and serum sHLA-G levels were measured using an ELISA assay, while pDCs (BDCA-2(+)) were accessed through flow cytometry analyses. Results CSF levels of NfL were significantly reduced during NTZ treatment, while the serum levels of sHLA-G were increased. Moreover, NTZ treatment enhanced tolerogenic (HLA-G(+), CD274(+), and HLA-DR+) molecules and migratory (CCR7(+)) functions of pDCs in the peripheral blood. Conclusion These findings suggest that NTZ stimulates the production of molecules with immunoregulatory function such as HLA-G and CD274 programmed death-ligand 1 (PD-L1) which may contribute to the reduction of axonal damage represented by the decrease of NfL levels in patients with MS. (AU)

• Processo FAPESP: 12/09879-2 - Estudo da função imunoreguladora da molécula HLA-G na Esclerose múltipla e na Encefalomielite experimental auto-imune.
• Beneficiário: Adriel dos Santos Moraes
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 14/26431-0 - Esclerose múltipla, estudo clínico, neuropsicológico, imunológico, biomarcadores e novas drogas modificadoras da doença
• Beneficiário: Leonilda Maria Barbosa dos Santos
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 13/00837-8 - Estudo dos mecanismos efetores e supressores induzidos pelos linfócitos B e células dendríticas plasmocitoides e interação com os linfócitos T de pacientes com esclerose múltipla em tratamento com o natalizumab
• Beneficiário: Alliny Carolina Dionete Lima
• Modalidade de apoio: Bolsas no Brasil - Doutorado